שווי פעילות לרווח לפני ריבית, מסים ופחת Akari Therapeutics Plc (AKTX)

Akari Therapeutics (AKTX) focuses on developing biopharmaceuticals to combat severe autoimmune disorders by utilizing complement regulation mechanisms. This price chart on GURU.Markets reflects an EV/EBITDA ratio of 0.00. The company is currently funded by investments as it develops treatments for orphan immune pathologies; however, post-merger integration and high costs associated with late-stage trials create significant financial risks.

This ratio correlates the total enterprise value with its operating profit before depreciation and amortization, allowing for the determination of the asset's fundamental undervaluation regardless of the debt load. An analysis of the EV/EBITDA metric for a capital-intensive business helps assess the efficiency of Akari Therapeutics (AKTX), taking into account the costs of environmental modernization of laboratories and the implementation of biodegradable packaging as part of its ESG strategy.